Searching map area
In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials
? TBD
scientific article published on November 2006
2006
Nobody has rated this yet. Be the first!
Lists 0
Abstract

The cyclin-dependent protein kinases are key regulators of cell cycle progression. Aberrant expression or altered activity of distinct cyclin-dependent kinase (CDK) complexes results in escape of cells from cell cycle control, leading to unrestricted cell proliferation. CDK inhibitors have the potential to induce cell cycle arrest and apoptosis in cancer cells, and identifying small-molecule CDK inhibitors has been a major focus in cancer research. Several CDK inhibitors are entering the...

Authors Wanda DePinto, Xin-Jie Chu, Xuefeng Yin, Melissa Smith, Petra Goelzer, Allen Lovey, Yingsi Chen, Hong Qian, Rachid Hamid, Qing Xiang, Christian Tovar, Roger Blain, Tom Nevins, Brian Higgins, Bernardo Felix, Sazzad Hussain, David Heimbrook
Volume Vol. 5, No. 11, pp. 2644-2658
Reading
Instance of
Subject
References